Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Risperdal Lawsuit News: Rottenstein Law Group LLP Comments on $2 Billion Risperdal Settlement Report

November 8, 2013

The firm is currently offering Risperdal lawsuit evaluations to those who allege that they suffered from the drug’s alleged side effects.

(PRWEB) November 08, 2013

Drug maker Johnson & Johnson has agreed to pay $2.2 billion in civil and criminal fines to settle claims it improperly marketed the antipsychotic medication Risperdal to children, seniors and people with developmental disabilities. The Rottenstein Law Group LLP, which represents clients in Risperdal lawsuits, notes that the federal government has reported that there are health risks associated with use of the drug among those groups.

The United States Department of Justice announced the settlement, which also includes heart-failure drug Natrecor and the antipsychotic Invega, according to a Nov. 4 New York Times story.* The federal government alleges J&J marketed the drug to high-risk groups between 1999 and 2005, the story said, adding that part of the settlement includes J&J pleading guilty to a criminal misdemeanor for its role in promoting the drug to those groups (United States of America v. Janssen Pharmaceuticals, Inc.; 13-605; U.S. District Court for the Eastern District of Pennsylvania).

Risperdal has been shown to nearly double the risk of heart disease and pneumonia in elderly dementia patients, according to the U.S. Food and Drug Administration.**

“Unfortunately, that $2.2 billion represents criminal and civil fines, not money to compensate victims,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “Those injured by Johnson & Johnson’s actions should consider retaining an attorney to assist them in seeking to obtain compensation for harms allegedly suffered from use of the drug."

The Rottenstein Law Group LLP encourages those who believe they or their loved ones have suffered from the alleged side effects of Risperdal to visit the firm's website to learn more about Risperdal lawsuits and side effects.

*nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html

**http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm152291.htm


About THE ROTTENSTEIN LAW GROUP LLP

The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:

The Rottenstein Law Group LLP

Rochelle Rottenstein, Esq.

321 W. 44th Street

# 804

New York NY 10036

(212) 933-9500 (office phone)

(212) 933-9980 (facsimile)

rochelle (at) rotlaw (dot) com

plus.google.com/106070664376281033016

For the original version on PRWeb visit: http://www.prweb.com/releases/risperdal-lawsuits/heart-failure/prweb11315249.htm


Source: prweb